Scisparc

Scisparc EBIT per Employee

The EBIT per Employee of Scisparc (SPRC) as of Nov 21, 2026 is -2.92 M USD. In the previous year, EBIT per Employee was -2.44 M USD — a change of 19.59% (lower).

EBIT per Employee

-2.92 MUSD

YoY

19.59%

Last updated:

EBIT per Employee of Scisparc is 2025 -2.92 M USD. EBIT per Employee of Scisparc was 2024 -2.44 M USD. It decreases by 19.59% lower compared to the previous year.

The Scisparc EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-3.24 M USD
Jan 1, 2019
-1.37 M USD
Jan 1, 2020
-1.10 M USD
Jan 1, 2021
-1.92 M USD
Jan 1, 2022
-2.46 M USD
Jan 1, 2023
-1.92 M USD
Jan 1, 2024
-2.44 M USD
Jan 1, 2025
-2.92 M USD
The Scisparc EBIT per Employee history
YEAREBIT per EmployeeYoY
-2.92 MUSD+19.59%
-2.44 MUSD+26.73%
-1.92 MUSD-21.78%
-2.46 MUSD+27.95%
-1.92 MUSD+75.16%
-1.10 MUSD-19.84%
-1.37 MUSD-57.71%
-3.24 MUSD+68.82%
-1.92 MUSD+188.12%
-665,696.10USD-21.74%
-850,654.67USD+43.54%
-592,631.77USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

EBIT per Employee of Scisparc is -2.92 M USD in 2025.

EBIT per Employee of Scisparc changed from -2.44 M USD to -2.92 M USD, representing a 19.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Scisparc since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Scisparc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Scisparc

All Key Metrics — Scisparc